Beam Therapeutics Q3 EPS $(1.28) Misses $(1.15) Estimate, Sales $307.000K Miss $8.752M Estimate
Benzinga Newsdesk 21 hours ago
NewsEarningsEarnings Misses
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(1.15) by 11.3 percent. This is a 16.36 percent decrease over losses of $(1.10) per share
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(1.15) by 11.3 percent. This is a 16.36 percent decrease over losses of $(1.10) per share from the same period last year. The company reported quarterly sales of $307.000 thousand which missed the analyst consensus estimate of $8.752 million by 96.49 percent. This is a 96.83 percent decrease over sales of $9.698 million the same period last year.